Veronica DiCamillo represents public and private companies, private equity funds, and investment banks in mergers and acquisitions, private equity investments, and securities law and corporate governance matters. Veronica advises on diverse US and cross-border acquisitions and dispositions, investments, joint ventures, tender offers, spinoffs, venture capital financings, and corporate reorganizations. In addition, she counsels on securities law compliance, corporate governance, and other general corporate matters. She is admitted in New York only, and her practice is supervised by New Jersey Bar members.
Veronica’s broad client base spans a variety of industries, including technology services, pharmaceuticals and healthcare, manufacturing, consumer goods and retail, media and entertainment, and shipping.
Additionally, Veronica is actively engaged in pro bono work, with a focus on counseling nonprofits on various legal issues and representing individual clients in asylum cases.
Before joining Morgan Lewis, Veronica was senior counsel in the corporate department of another global law firm, resident in New York. As a junior associate, she completed a secondment at UBS Investment Bank.
Prior to graduating law school, Veronica served as a member of the Fordham Law Review and interned with Judge Shira Sheindlin in the US District Court for the Southern District of New York.
Strategic Mergers & Acquisitions
Represented a US public technology company in connection with its acquisition of a consulting business.
Represented PotashCorp in connection with its $38 billion all-stock merger of equals with Agrium.
Represented Valeant Pharmaceuticals International, Inc. in connection with its acquisition through a tender offer of Obagi Medical Products, Inc. The transaction was valued at $440 million.
Represented Pfizer, Inc. in connection with the global restructuring and spinoff of its Animal Health business, which is now Zoetis, Inc., and the global restructuring and $11.8 billion sale of its Nutrition business to Nestlé S.A.
Represented Chindex International, Inc. in connection with its going-private transaction.
Represented a division of CVS Pharmacy in its acquisition of two home healthcare businesses.
Represented a large pharmaceutical company in connection with purchasing an option to acquire a company upon the FDA’s approval of its drug.
Represented a US financial institution in connection with the sale of its railcar leasing portfolio.
Represented an investment firm in its $100 million acquisition of a Swiss private bank.
Represented a privately held financial services firm in connection with its $535 million acquisition of a commercial financing and leasing company.
Represented a US-based cable television provider/multiple system operator in an auction involving the sale of certain of its cable assets and entities to a US private equity firm. The transaction was valued at $500 million.
Represented a US private equity investment firm in connection with the divestiture of its minority interest in four entertainment companies.
Represented a US private equity investor in its acquisition of a leading global experiential marketing solutions company.
Represented a US private equity investor in connection with the sale of a publisher of unabridged audiobooks and provider of digital content to the library, school, and retail markets.
Represented a US private equity investor in connection with its minority investment in a mobile technology accessory manufacturer.
Represented a US private equity investor in connection with the sale of its truck dealership group to a US private equity firm.
Represented a large pharmaceutical company in connection with its minority investment in a startup maker of personalized medicine suites.
Fordham University School of Law, 2007, J.D.
New York University, 2004, B.A., Economics and Fine Arts, cum laude